Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

By A. Garber, R. Henry, R. Ratner, P. García-Hernández, Hiromi Rodriguez-Pattzi, I. Olvera-Alvarez, P. M. Hale, M. Zdravkovic, B. Bode. The Lancet, 2009

1,136 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/4bee02c792b08d69e59e76c3e27429bfa6b02fa7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (2009, background): “Similar patterns are apparent in other studies.[13-15,18,19] Only two major hypoglycaemic episodes occurred (both in the exenatide group).”
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes (2008, background): “Sulfonylurea 9 (11) 12 (13) 11 (13) 7 (8) 3 (7)”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “In addition, the HbA1c reduction with liraglutide (1.8 mg) was higher than that with other doses [191] .”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “The most frequently reported adverse events were nausea and vomiting, especially at the higher doses, and two cases of pancreatitis have been reported (Amori et al., 2007; Vilsbøll et al., 2007; Garber et al., 2008b; Madsbad, 2008).”